2019
DOI: 10.23736/s0393-2249.19.03420-9
|View full text |Cite
|
Sign up to set email alerts
|

Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
4
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 66 publications
1
4
0
Order By: Relevance
“…The added SRE risk in patients with BESM was also identified by Tanaka and colleagues in a cohort of 534 breast cancer women who developed bone metastases [19]. The present study confirms that result in a large cohort of mCRPC patients, and taken together these findings challengethe current trend towards a reduced BTA scheduling frequency from every 4 weeks to every 12 weeks (especially for ZA) across all mCRPC patients [16,25,26]. Specifically, this study supports the hypothesis that the metastatic compartment has impact in bone outcomes and may be taken into account when considering de-escalation strategies to better tailor such approaches.…”
Section: Discussionsupporting
confidence: 90%
“…The added SRE risk in patients with BESM was also identified by Tanaka and colleagues in a cohort of 534 breast cancer women who developed bone metastases [19]. The present study confirms that result in a large cohort of mCRPC patients, and taken together these findings challengethe current trend towards a reduced BTA scheduling frequency from every 4 weeks to every 12 weeks (especially for ZA) across all mCRPC patients [16,25,26]. Specifically, this study supports the hypothesis that the metastatic compartment has impact in bone outcomes and may be taken into account when considering de-escalation strategies to better tailor such approaches.…”
Section: Discussionsupporting
confidence: 90%
“…ZA effectively reduces SRE risk in patients with mCRPC [ 41 ]. Our meta-analysis of SREs is consistent with this conclusion, with the subgroup analysis of SREs also indicating that patients with M1 metastasis had a significant decrease in SREs.…”
Section: Discussionmentioning
confidence: 99%
“…223Ra is approved by the FDA for the treatment of mCRPC patients with bone-related symptoms or localized bone metastases and is the only drug found to improve metastatic castration-resistant prostate cancer. The European MedicineAgency (EMA) has also approved 223Ra for the treatment of patients with bone metastases who have had two mCRPC bone treatments or are unable to receive other treatment options [75].…”
Section: Radium-223223ramentioning
confidence: 99%
“…Compared with 223Ra, the β particles produced by the decay of 89Sr after absorption into bone have lower energy and wider radiation range than α particles, which may make the destruction effect of 89Sr on metastatic bone tumors lower than that of 223Ra. It's also more likely to cause damage to normal bone tissue [75][76][77][78]. The combination of 89Sr and ZA has been widely used for bone metastasis of lung cancer.…”
Section: Strontium-89 89srmentioning
confidence: 99%